TABLE 1

Demographic and clinical characteristics of XDR-TB patients enrolled in this study

CharacteristicExperimental group (n = 22)Control group (n = 27)P
Age (mean [range]) (yr)42.40 (25–65)42.46 (20–62)0.987
Male (no. [%])17 (77.3)19 (70.4)0.587
Body mass index (mean [range]) (kg/m2)18.91 (12.91–25.35)21.15 (12.49–26.75)0.191
Treatment history (no. [%])
    New case0 (0.0)3 (11.1)0.310
    Previously treated case22 (100.0)24 (88.9)
Treatment duration for previously treated patients (mean [range]) (mo)36.14 (9–96)24.96 (1–66)0.194
Comorbidity (no. [%])
    Diabetes mellitus1 (4.5)1 (3.7)1.000
    COPDa1 (4.5)2 (7.4)
    Cardiopathy0 (0.0)1 (3.7)
Course of disease (no. [%])
    ≤1 y before randomization0 (0.0)4 (14.8)0.221
    >1 y to 3 y before randomization6 (27.3)7 (25.9)
    >3 y before randomization16 (72.7)16 (59.3)
Previous treatment (no. [%])
    ≤1 y before randomization1 (4.5)5 (18.5)0.265
    >1 y to 3 y before randomization10 (45.5)13 (48.1)
    >3 y before randomization11 (50.0)9 (33.3)
Susceptibility test result of resistance (no. [%])
    Isoniazid22 (100.0)27 (100.0)
    Rifampin22 (100.0)27 (100.0)
    Ethambutol13 (59.1)16 (59.3)0.990
    Ofloxacin22 (100.0)27 (100.0)
    Amikacin22 (100.0)27 (100.0)
    Capreomycin20 (90.9)24 (88.9)1.000
No. of drugs with resistance (median [range])6.0 (4–8)6.0 (4–8)
Background regimen (no. [%])
    Prothionamide22 (100.0)27 (100.0)
    Pyrazinamide22 (100.0)27 (100.0)
    Moxifloxacin or levofloxacin22 (100.0)27 (100.0)
    p-Aminosalicylic acid20 (90.9)22 (81.5)0.598
    Capreomycin or amikacin19 (86.4)23 (85.2)1.000
    Ethambutol22 (100.0)27 (100.0)
  • a COPD, chronic obstructive pulmonary disease.